Sentences with phrase «hiv vaccine study»

I was doing this HIV vaccine study and getting weighed each month while I was losing my weight.

An exception to this trend is Dong Pyou Han, a former Iowa State University (ISU) biomedical researcher who last week was sentenced to prison for 57 months — almost 5 years — for falsifying results in HIV vaccine studies he participated in while working under lab head Michael Cho, The Guardian reports.

Dr. Polonis has coordinated regional labs in Thailand and East Africa for the Duke University Comprehensive Antibody Vaccine Immune Monitoring Consortium (CA - VIMC) funded by the Bill and Melinda Gates Foundation, and is a standing member of the HIV Vaccines Study Section for the Center for Scientific Review at the NIH.

Not exact matches

«New study has important implications for the design of a protective HIV vaccine.»

The study has important implications for the design of a protective HIV vaccine.

Researchers for the past decade have focused on the T cell approach, based on studies showing that monkeys receiving such vaccines against simian immunodeficiency virus, related to HIV, lived longer or had lower viral levels than usual.

Using the findings from this study, the team has designed vaccine immunogens to selectively trigger the cooperating antibody - producing B cells to cooperate to make broadly neutralizing antibodies in a manner that mimics broadly neutralizing antibody development in natural HIV infection.

«We are pleased to have demonstrated such a potent and durable immune response to the vaccine,» said the study's lead author, Sita Awasthi, PhD, a research associate professor of Infectious Diseases at Penn. «If found effective in clinical trials, the vaccine will have a huge impact on reducing the overall prevalence of genital herpes infections and could reduce new HIV infections as well, especially in high - burden regions of sub-Saharan Africa.»

A new study has cast fresh doubts on an AIDS vaccine that was abandoned in 2007 because of fears that it made some recipients more susceptible to HIV infection.

But vaccines that only contained HIV's surface protein looked lackluster in animal and test tube studies, and then proved worthless in large - scale clinical trials.

«The ability to identify the glycan fingerprint on HIV's glycoprotein will help us develop a vaccine that matches what is found on the virus,» said James Paulson, Cecil H. and Ida M. Green Chair of Chemistry at TSRI and co-chair of the Department of Molecular Medicine, who led the study published in the journal Nature Communications.

The pilot study is part of a larger study investigating the possibilities of combining activation of HIV and a vaccine to strengthen the ability of the immune system to fight HIV.

To address that debate, Kojic's study, dubbed «AIDS Clinical Trials Group Protocol 5240,» measured the safety and immune system response of the vaccine in HIV - positive women aged 13 to 45 with a wide range of immune statuses.

In the RV144 study, the combination vaccine was 31.2 percent effective at preventing HIV infection — a success rate that was unprecedented, but considered too low to advance the vaccine to common use.

The study, published Aug. 13, 2014, in the journal Cell Host & Microbe, builds on previous work from researchers at the Duke Human Vaccine Institute that outlined a perplexing quality about HIV: The antibodies that originally arise to fight the virus are ineffective.

«We learned in this study that grabbing hold of these glycans can be a very important early step in an effective immune response to HIV, and with this knowledge, we believe we can design better candidate vaccines,» said principal investigator Dennis R. Burton, professor of immunology and microbiology at TSRI.

Researchers led by a team at Duke University identified these immunologic variations by studying blood samples collected from people living with HIV by the NIAID - supported Center for HIV / AIDS Vaccine Immunology (CHAVI).

LONDON (Reuters)-- Researchers announced the launch of two big studies in Africa on Thursday to test a new HIV vaccine and a long - acting injectable drug, fuelling hopes for better ways to protect against the virus that causes AIDS.

Of more than 50 therapeutic vaccine trials so far, this is the first one that has bolstered the immune system in a «meaningful» way, says Steven Deeks, an HIV / AIDS clinician and researcher at the University of California, San Francisco, who is «cautiously optimistic» that the data will inspire others to study the approach.

The results, which need to be confirmed in larger studies, suggest the vaccine may boost the immune system enough to allow infected people to drive down HIV levels without taking drugs — although it's not clear for how long.

«Results from a former AIDS vaccine study have shown that in a worst case scenario, immunization against HIV could enhance infection,» says Christiane Stahl - Hennig, who designed the project in cooperation with the former DPZ employee Sieghart Sopper.

An earlier form of the vaccine was used in the DarDar Trial, a seven - year study in Tanzania sponsored by the U.S. National Institutes of Health involving patients with HIV infection who at birth had received BCG, the current tuberculosis vaccine.

«In line with our company's commitment to address global health needs, we are committed to working with leading experts to develop a preventative HIV vaccine and our team is excited to advance this program into human clinical studies.»

Notably, the discovery of naturally occurring broadly neutralizing antibodies against HIV and studies of their stimulation in infected individuals have opened new avenues in vaccine development.

A new study led by scientists at Beth Israel Deaconess Medical Center (BIDMC) shows that an HIV - 1 vaccine regimen, involving a viral vector boosted with a purified envelope protein, provided complete protection in half of the vaccinated non-human primates (NHPs) against a series of six repeated challenges with simian immunodeficiency virus (SIV), a virus similar to HIV that infects NHPs.

An HIV - 1 version of the promising vaccine regimen is now being evaluated in an ongoing Phase 1 / 2a international clinical study.

Based on these pre-clinical data, the HIV - 1 version of this vaccine regimen is now being evaluated in an ongoing Phase 1 / 2a international clinical study sponsored by Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

The researchers» next steps will be to conduct longer - term studies in combination with other vaccine candidates, hone in on what areas of gp120 the antibodies are binding to and determine how they can increase the antibodies» effectiveness at neutralizing HIV.

«Bringing the global HIV epidemic under control requires new tools, bold strategies and collaboration among a number of stakeholders,» said Hanneke Schuitemaker, one of the study authors and vice president, Viral Vaccines Discovery and Translational Medicine, Janssen.

Infection of mice with these viruses has been successfully applied to study aspects of HIV neuropathogenesis and to evaluate antiretroviral drugs and potential HIV vaccines.

«New findings to help HIV scientists establish «template» for potent antibodies: Natural - infection studies in Africa and India continue to inform HIV vaccine design.»

«Uncovering the process by which neutralizing antibodies develop is critical to HIV vaccine design,» said Elise Landais, Senior Research Scientist with IAVI and lead author of the study.

AIDS researcher Jay Levy at the University of California at San Francisco finds the results encouraging, but notes that the vaccines seemed to have no effect on the amount of virus in the bloodstream of people who contracted HIV during the study.

Batista was one of a number of scientists involved in the study from the Ragon Institute, established in the Boston area by experts from Massachusetts General Hospital, Harvard University and the Massachusetts Institute of Technology, with the goal of working toward development of an effective vaccine against HIV / AIDS.

In recent years, other groups have done small studies in people already infected with HIV using a vaccine made from the virus itself.

If you decide to participate in an HIV Vaccine Trials Network (HVTN) study, you will be given a copy of this document in one of these languages, depending on your preference.

SEATTLE, WA and DURHAM, NC — The HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN) today announced the initiation of HVTN 704 / HPTN 085, also known as Antibody Mediated Prevention (AMP) or the AMP Study, a Phase 2b clinical trial to evaluate the safety and efficacy of VRC01, a broadly neutralizing monoclonal antibody (bnAb).

The HVTN 100 study is part of a larger HIV vaccine research endeavor led by a group called the Pox - Protein Public - Private Partnership, or the P5 — a diverse set of public and private organizations, including MHRP, committed to building on the success of RV144.

This experimental vaccine regimen is based on the one tested in the U.S. Military HIV Research Program - led RV144 clinical trial in Thailand — the first study to demonstrate that a vaccine can protect people from HIV infection.

While studying a group of women at risk of HIV in Mombasa, Kenya, Dr. Julie Overbaugh and colleagues found a potential vulnerability in the AIDS virus that could lead to clues for designing an effective vaccine.

«In the future, [the findings] could apply to vaccines that we hope will be developed against generally lethal viruses (e.g. HIV, Ebola), encouraging scientists to strive towards «perfect vaccines» for them,» Michael Skinner, a virologist from Imperial College London who wasn't part of the study, told the Science Media Centre.

Five years ago, he enrolled in a study at the UNC School of Medicine, which was part of Dr. David Margolis» «kick and kill» strategy for eradicating HIV by flushing it out of hiding with a drug called Vorinostat and killing it with either a vaccine

Data from a study done 20 years ago on maternal - infant HIV transmission give clues that could lead to better HIV vaccine design

Results from an initial study to ensure that the RV144 vaccine regimen is safe and well - tolerated in South African volunteers were reported at the 2014 HIV Research for Prevention (R4P) conference.

Sharma's focus will be on engineering a simian HIV virus that will work for these vaccine studies.

MHRP's international research program has six clinical research sites in the U.S., Africa and Asia, where it conducts HIV cohort studies, HIV vaccine trials and therapeutic studies.

The Step study, an international HIV vaccine trial co-sponsored by the National Institute of Allergy and Infectious Diseases and the pharmaceutical company Merck, was halted in 2007 when the vaccine failed to prevent HIV infection in volunteers or affect the virus load in those infected.

Building on the findings of an earlier study that found for the first time, albeit modestly, that a vaccine could prevent HIV infection in 2016, an NIH - supported clinical trial was launched to test a modified HIV vaccine.

As the Global HIV Vaccine Product Manager for the US Army, Dr. Ake advances the development of HIV vaccine candidates in preclinical and early clinical sVaccine Product Manager for the US Army, Dr. Ake advances the development of HIV vaccine candidates in preclinical and early clinical svaccine candidates in preclinical and early clinical studies.

This HIV vaccine research study is being conducted in collaboration with Muhimbili University (MUHAS)